<DOC>
	<DOCNO>NCT02196207</DOCNO>
	<brief_summary>This study evaluate inhibitor reduce Eloctate begin child severe Hemophilia A first bleed ( preemptive ) continue weekly prevent bleeds ( prophylaxis ) .</brief_summary>
	<brief_title>Hemophilia Inhibitor Prevention ( INHIBIT ) Trial</brief_title>
	<detailed_description>This outpatient , 48-week open-label single-arm Phase II clinical trial preemptive long-acting recombinant factor VIII Fc fusion protein , Eloctate , child severe hemophilia A prevent inhibitor formation . Eloctate recently approve FDA treatment prevention bleeds hemophilia . In trial , Eloctate evaluate prevention inhibitor child hemophilia A . The research trial consider great minimal risk involve initiate weekly dose first bleed obtain special inhibitor study . Preemptive refers initiate prophylaxis first bleed . Prophylaxis refers give preventive factor prevent bleeds . In study , begin age 4 month , child severe hemophilia A enrol `` first bleed , '' purpose study first bleed require factor treatment ( exclude circumcision ) . A total 65 subject enrol one 41+ HTCs , 1-4 per site , include 4 site . Following enrollment , subject begin preemptive prophylaxis Eloctate 50 IU/kg weekly first bleed .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Male child &gt; /= 4 month age . Severe hemophilia A ( F.VIII &lt; 0.01 U/ml ) No previous bleed surgery require treatment ( except circumcision ) No previous factor VIII product ( except circumcision ) Willingness comply weekly prophylaxis 48 week Willingness parent/caregiver keep personal diary bleeding frequency factor treatment . Willingness make monthly visit coagulation test week 4 , 12 , 24 , 36 , 48 ( end study ) Acquired hemophilia Any bleed disorder hemophilia A Treatment clot factor previously , circumcision Presence inhibitor factor VIII Use experimental drug ( ) Surgery anticipate next 48 week Life expectancy le 5 year Inability comply study requirement</criteria>
	<gender>Male</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Severe Hemophilia A</keyword>
	<keyword>Previously Untreated Patients</keyword>
	<keyword>Hemophilia Inhibitor Formation</keyword>
	<keyword>Long-Acting Factor VIII</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>